Effects of the dopamine-related drug bromocriptine on event-related potentials and its relation to the law of initial value.
Effects of the dopamine-related drug bromocriptine (BCT) on event-related potentials (ERP) were investigated in 18 healthy volunteers. Bromocriptine 2.5 mg or an inactive placebo was administered according to a completely randomized double-blind, cross-over design. The ERP were recorded 3 h after medication was given. Although BCT prolonged the P300 latency, it had no effect on the amplitudes of the ERP components as a whole. Bromocriptine increased the latencies of N100, P200 and P300 in the respective short-latency subject group, and decreased the latency of N200 in the long-latency subject group. It increased the amplitude of N200 in the low-amplitude subject group. It was concluded that the prolongation of P300 latency as a whole and the different responses that take place are dependent on the initial values and were recognized in the effect of a single administration of BCT 2.5 mg. The results of this study are discussed in relation to the law of initial value.
Nishimura
N
N
Department of Neuropsychiatry, School of Medicine, University of the Ryukyus, Okinawa, Japan.
Ogura
C
C
Ohta
I
I
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004876:Ergot Alkaloids / Q000494:pharmacology*; D005071:Evoked Potentials / Q000187:drug effects*; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D006801:Humans; D008297:Male; D010919:Placebos
D004876:Ergot Alkaloids; D010919:Placebos; D001971:Bromocriptine